The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

David R. Brennan net worth and biography

David Brennan Biography and Net Worth

Director of Insmed

Mr. Brennan joined our board in May 2014, bringing more than 37 years of experience in the pharmaceutical industry. He was appointed lead independent director in November 2018. From 2006 to 2012, Mr. Brennan was the Chief Executive Officer of AstraZeneca PLC, a global biopharmaceutical company. Previously at AstraZeneca, Mr. Brennan served as Executive Vice President of North America from 2001 to 2006; and as Senior Vice President of Commercialization and Portfolio Management from 1999 to 2001. Mr. Brennan also served as a member of the board of directors of AstraZeneca from 2005 to 2012. Prior to AstraZeneca, Mr. Brennan held various positions at Astra Pharmaceuticals, L.P., Astra Merck, Inc. and Merck and Co. Inc. Mr. Brennan previously served as chairman of the board of directors of Alexion Pharmaceuticals until its acquisition by AstraZeneca in July 2021 and previously served as Interim CEO of Alexion from December 2016 to March 2017. Mr. Brennan received a B.A. in Business Administration from Gettysburg College. He is a member of the Compensation Committee.

How do I contact David R. Brennan?: The corporate mailing address for Mr. Brennan and other Insmed executives is 700 US Highway 202/206, Bridgewater NJ, 08807. Insmed can also be reached via phone at 908-977-9900 and via email at [email protected]. Learn More on David R. Brennan's contact information.
Has David R. Brennan been buying or selling shares of Insmed?: David R. Brennan has not been actively trading shares of Insmed during the past quarter. Most recently, on Monday, November 1st, David R. Brennan bought 10,000 shares of Insmed stock. The stock was acquired at an average cost of $30.15 per share, with a total value of $301,500.00. Learn More on David R. Brennan's trading history.
Who are Insmed's active insiders?: Insmed's insider roster includes Roger Adsett (COO), Sara Bonstein (CFO), David Brennan (Director), Martina Flammer (Insider), William Lewis (CEO), Orlov Nicole Schaeffer (Insider), Melvin Sharoky (Director), Michael Smith (VP), and John Wise (Insider). Learn More on Insmed's active insiders.
Are insiders buying or selling shares of Insmed?: In the last year, insiders at the biopharmaceutical company sold shares 18 times. They sold a total of 271,590 shares worth more than $7,211,082.98. The most recent insider tranaction occured on January, 12th when insider Martina M.D. Flammer sold 4,667 shares worth more than $133,616.21. Insiders at Insmed own 4.6% of the company. Learn More about insider trades at Insmed.
Information on this page was last updated on 1/12/2024.

David R. Brennan Insider Trading History at Insmed

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/1/2021	Buy	10,000	$30.15	$301,500.00

David R. Brennan Buying and Selling Activity at Insmed

Insmed Company Overview

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Today's Range

Now: $24.92

$24.81

$25.44

50 Day Range

MA: $27.24

$24.11

$29.51

2 Week Range

Now: $24.92

$18.08

$32.00

Volume

1,206,866 shs

Average Volume

1,773,005 shs

Market Capitalization

$3.70 billion

P/E Ratio

N/A

Dividend Yield